MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Design of ORCHESTRA Study: Practical Experiences With Foslevodopa/Foscarbidopa Treatment in Advanced Parkinson’s Disease

    A. Johansson, E. Pekkonen, L. Dorresteijn, P. Schwingenschuh, J. Szász, L. Bergmann, M. O'Meara, J. Parra, M. Südmeyer (Helsinki, Finland)

    Objective: To describe the practical management of foslevodopa/foscarbidopa (LDp/CDp) for treating advanced Parkinson’s disease (aPD) in routine clinical practice using data collected through a patient…
  • 2025 International Congress

    Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis

    N. Smith, B. Amlani (Reading, United Kingdom)

    Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…
  • 2025 International Congress

    Apomorphine Sublingual Film’s Efficacy in Elderly Patients with Parkinson’s Disease: Post-hoc Analysis of Study CTH-301

    F. Moreira, L. Wojtecki, W. Jost, D. Santos Garcia, J. Kassubek, M. Fonseca, H. Brigas, G. Harrison-Jones, I. Pijuan (Duesseldorf, Germany)

    Objective: This study evaluated the efficacy of apomorphine sublingual film (SL-APO) in elderly (≥70 years) and younger (<70 years) patients over the long term. Background:…
  • 2025 International Congress

    Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease

    A. Castro Mejia, S. Sapienza, L. Pavelka, R. Kruger, J. Klucken (Belvaux, Luxembourg)

    Objective: To estimate medication effect, as the score difference between MDS-UPDRS III in OFF and ON-state, using a minimal set of clinical features. Background: The…
  • 2025 International Congress

    Seven-year follow-up of clinical and neurophysiological features in essential tremor

    L. Angelini, S. Grandolfo, D. Birreci, D. Costa, M. de Riggi, A. Martini, S. Aloisio, A. Cannavacciuolo, S. Agkun, G. Paparella, M. Bologna (Pozzilli IS, Italy)

    Objective: To prospectively follow-up a sample of Essential Tremor (ET) patients to identify trends in the progression of motor and cognitive symptoms. Background: ET is…
  • 2025 International Congress

    Repetitive Transcranial Magnetic Stimulation For Freezing Of Gait And Motor Function In Parkinson’s Disease: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials

    J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) on motor function, freezing of gait (FOG), and mobility in patients with Parkinson’s disease…
  • 2025 International Congress

    The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease

    I. Malaty, P. Odin, D. Kern, L. Bergmann, M. Shah, R. Gupta, A. Antonini, K. Chaudhuri (Gainesvile, USA)

    Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…
  • 2025 International Congress

    Targeting IGF2 Signaling for Immune Modulation of Microglia in Parkinson’s Disease

    T. Huerta, V. Urbina, C. Aguilera, P. Chana, R. Vidal (Santiago, Chile)

    Objective: We propose that IGF2 induces a distinct inflammatory phenotype in macrophages or microglia derived from Parkinson’s disease (PD) patients. Background: Microglia are the resident…
  • 2025 International Congress

    The neuroprotective effects of Echinacoside on α-synuclein fibril-induced Parkinson’s disease mice model

    Q. Zhao, S. Bu, Z. Wang, L. Jin (Shanghai, China)

    Objective: This study further investigates the ameliorative effects of ECH on neurobehavioral abnormalities and nigrostriatal dopaminergic system impairment in α-synuclein preformed fibrils (α-Syn PFFs)-induced PD…
  • 2025 International Congress

    Alpha-Synuclein Aggregates in the Olfactory Epithelium of Subjects with Parkinson Disease, Dementia, COVID-19, and in Aged Controls

    J. Tomlinson, N. Lengacher, A-K. Jochum, J. Franz, L. Flatz, B. Mollenhauer, C. Stadelmann, J. Woulfe, M. Schlossmacher (Ottawa, Canada)

    Objective: We sought to examine whether neuroepithelial structures of the nasal cavity differ between individuals diagnosed with a Lewy body disorder vs those with COVID19…
  • « Previous Page
  • 1
  • …
  • 333
  • 334
  • 335
  • 336
  • 337
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley